Business Wire

MA-NETCRACKER-TECHNOLOGY

3.6.2020 14:02:09 CEST | Business Wire | Press release

Share
Netcracker 2020 Puts Service Providers at the Center of the Digital Economy

Netcracker Technology announced today the launch of its Netcracker 2020 portfolio to help service providers focus on their customer’s digital lifestyle. With Netcracker 2020 , service providers can transform customer engagement, dynamically evolve their digital ecosystems and reach new levels of automation and security, helping them to innovate and disrupt in the 5G digital economy.

Netcracker 2020 Digital BSS /OSS and Customer Engagement products and services have been redesigned and enhanced for the 5G era. The new digital portfolio is fully open and standards compliant, built for the cloud and allows service providers to develop their own enhancements or co-develop functions through a low code platform and blueprint delivery approach. With continuous short releases using Agile/DevOps processes, service providers gain faster access to innovative features with no disruptions to business operations. Central to Netcracker 2020 is an industry-leading security framework, designed to provide the highest level of proven system-wide security and privacy, which is critical in an era of increased cyber-attacks, intrusion and disruption.

In addition, as the world prepares for the uncertainty of a post COVID-19 environment, service providers want to increase the effectiveness of remote consumer and business interactions. With Netcracker 2020, they can radically transform customer engagement by anticipating their needs using AI-driven contextual interactions that go beyond problem solving and deliver relevant new services that combine service providers’ own services with those from partners and enriched with 5G experiences. As customers’ requirements become even more of a priority for service providers, personalized offerings can be dynamically created and delivered with a ground-breaking gaming-style user experience and cross-partner loyalty schemes.

Evolving to a more partner-based digital economy will require management of complex relationships, interconnections and business models with new and constantly changing partners, including other service providers. Netcracker 2020 helps build dynamic digital ecosystems that quickly adapt to changing business and market needs. With automated onboarding, simplified lifecycle management and partner-centric B2B2X opportunities, service providers will become both leaders and enablers of new platform-based monetization opportunities in diverse markets.

As services, networks and partnerships become more complex, full automation at every level has become a necessity. Netcracker 2020 uses a new operational model to remove manual tasks and drive hyper automation across network domains, services that cross domains, business processes and channels that are quickly moving towards open 5G networks with cloud-native functions and highly demanding edge cloud applications. Netcracker 2020 digital applications are cloud-native and designed to run in a multicloud environment, delivering the same high performance and resiliency on public clouds as on-premise cloud platforms. This also includes a security architecture and trust center that has become the industry benchmark.

“As BSS/OSS becomes increasingly critical to assure customer experience and enable security and flexible services, Netcracker has strengthened its position as the leader in helping service providers succeed in the highly competitive digital economy,” noted Sue Rudd, Director Networks and Service Platforms at Strategy Analytics. “Netcracker 2020 offers service providers a highly automated, multi-vendor microservices based environment to address their customers’ dynamic digital needs and sets the benchmark for modern BSS/OSS to accelerate revenue-generating service delivery in today’s uncertain world.”

“Netcracker 2020 is the culmination of over 25 years of experience of providing and operating mission-critical systems to hundreds of service providers around the globe in order to keep their businesses moving forward,” said Bob Titus, Chief Technology Officer, Netcracker. “This includes support for new business models, hyper automation, cloud adoption and the use of open source, outcome-based delivery models and, perhaps most importantly, an exceptional digital-first customer experience.”

About Netcracker Technology
Netcracker Technology, a wholly owned subsidiary of NEC Corporation, offers mission-critical digital transformation solutions to service providers around the globe. Our comprehensive portfolio of software solutions and professional services enables large-scale digital transformations, unlocking the opportunities of the cloud, virtualization and the changing mobile ecosystem. With an unbroken service delivery track record of more than 25 years, our unique combination of technology, people and expertise helps companies transform their networks and enable better experiences for their customers.

For more information, visit www.netcracker.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release

Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye